|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
|
WO2007015578A1
(ja)
*
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
|
AU2006309551B2
(en)
|
2005-11-07 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
|
ES2556173T3
(es)
*
|
2006-05-18 |
2016-01-13 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral para un cáncer de tiroides
|
|
KR101445892B1
(ko)
*
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
|
CN101848895B
(zh)
*
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
CN103476943A
(zh)
|
2011-03-10 |
2013-12-25 |
普罗维克图斯药品公司 |
用于增强治疗癌症的局部和全身性免疫调节疗法的组合
|
|
RU2580609C2
(ru)
*
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
KR102125658B1
(ko)
|
2012-05-04 |
2020-06-22 |
화이자 인코포레이티드 |
전립선 관련된 항원 및 백신 기재 면역치료 요법
|
|
US10034938B2
(en)
*
|
2012-08-30 |
2018-07-31 |
Amgen Inc. |
Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
TW201427681A
(zh)
*
|
2013-01-07 |
2014-07-16 |
Superlab Far East Ltd |
用空間構象改變的重組干擾素治療腫瘤的方法
|
|
US12421502B2
(en)
|
2013-04-18 |
2025-09-23 |
Tilt Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
|
DK3461491T3
(da)
|
2013-04-18 |
2025-02-03 |
Tilt Biotherapeutics Oy |
Forbedret adoptiv celleterapi
|
|
WO2014185540A1
(en)
|
2013-05-14 |
2014-11-20 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
CA2939941A1
(en)
*
|
2014-02-21 |
2015-08-27 |
Abbvie Stemcentrx Llc |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
PL3134123T3
(pl)
*
|
2014-02-21 |
2021-07-12 |
Nektar Therapeutics (India) Pvt. Ltd. |
Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1
|
|
KR20240144452A
(ko)
|
2014-03-05 |
2024-10-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
|
|
KR20170003692A
(ko)
|
2014-05-15 |
2017-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
|
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
|
WO2016106146A1
(en)
|
2014-12-23 |
2016-06-30 |
The Regents Of The University Of California |
Methods for immunomodulation of cancer and infectious disease therapy
|
|
CN104459129A
(zh)
*
|
2015-01-05 |
2015-03-25 |
复旦大学附属华山医院 |
一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
|
|
KR20250024102A
(ko)
|
2015-02-25 |
2025-02-18 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 고미 억제 방법
|
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
KR20250107941A
(ko)
|
2015-04-28 |
2025-07-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
|
|
KR20170138555A
(ko)
|
2015-04-28 |
2017-12-15 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
|
|
KR101997241B1
(ko)
|
2015-05-21 |
2019-07-09 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
|
PT3322731T
(pt)
|
2015-07-14 |
2021-02-25 |
Bristol Myers Squibb Co |
Método de tratamento de cancro utilizando inibidor de ponto de verificação (checkpoint) imunitário; anticorpo que se liga ao recetor de morte programada-1 (pd-1) ou ligando de morte programada 1 (pd-l1)
|
|
SG11201801083UA
(en)
|
2015-08-20 |
2018-03-28 |
Eisai R&D Man Co Ltd |
Tumor therapeutic agent
|
|
CA3004107C
(en)
|
2015-11-11 |
2023-10-17 |
Agalimmune Limited |
Glycolipid compounds and their uses in the treatment of tumours
|
|
CN108350081A
(zh)
|
2015-11-18 |
2018-07-31 |
百时美施贵宝公司 |
使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
|
|
US10130658B2
(en)
|
2015-12-18 |
2018-11-20 |
Provectus Pharmatech, Inc. |
Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
|
|
LT3394093T
(lt)
|
2015-12-23 |
2022-04-25 |
Modernatx, Inc. |
Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
|
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
|
US20190111111A1
(en)
*
|
2016-04-13 |
2019-04-18 |
The Regents Of The University Of California |
Treatment of Cerebral Cavernous Malformations
|
|
MX393869B
(es)
|
2016-05-18 |
2025-03-24 |
Modernatx Inc |
Polinucleotidos que codifican interleucina-12 (il12) y usos de los mismos.
|
|
JP7194594B2
(ja)
|
2016-05-18 |
2022-12-22 |
モデルナティエックス インコーポレイテッド |
免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用
|
|
AU2017268399B2
(en)
|
2016-05-18 |
2023-01-12 |
Modernatx, Inc. |
mRNA combination therapy for the treatment of cancer
|
|
JP7169195B2
(ja)
|
2016-05-20 |
2022-11-10 |
バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド |
癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
HRP20230864T1
(hr)
|
2016-06-02 |
2023-11-10 |
Bristol-Myers Squibb Company |
Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma
|
|
WO2017210631A1
(en)
|
2016-06-03 |
2017-12-07 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
|
|
CN109476754A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
抗-pd-1抗体在治疗结肠直肠癌患者中的用途
|
|
KR102634093B1
(ko)
|
2016-10-28 |
2024-02-07 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
|
|
AU2018209164B2
(en)
|
2017-01-17 |
2021-11-04 |
Heparegenix Gmbh |
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
AU2018243754B2
(en)
|
2017-03-31 |
2025-04-10 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
KR20190139225A
(ko)
|
2017-04-28 |
2019-12-17 |
머크 샤프 앤드 돔 코포레이션 |
암 치료제용 생물마커
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
US20200197384A1
(en)
|
2017-05-16 |
2020-06-25 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
CA3060989A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
GB201710097D0
(en)
*
|
2017-06-23 |
2017-08-09 |
Univ Ulster |
A sensitizer - peptide conjugate
|
|
CN111386117A
(zh)
|
2017-09-29 |
2020-07-07 |
百时美施贵宝公司 |
治疗癌症的组合物和方法
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
WO2019075359A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
TRISPECIFIC PROTEINS AND METHODS OF USE
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
CN111787918A
(zh)
*
|
2017-11-29 |
2020-10-16 |
洛克菲勒大学 |
用于皮肤病学病况增强治疗的局部和全身性治疗的组合
|
|
WO2019143607A1
(en)
|
2018-01-16 |
2019-07-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
EA202091751A1
(ru)
|
2018-01-22 |
2020-11-06 |
Бристол-Маерс Сквибб Компани |
Композиции и способы лечения рака
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
WO2019191676A1
(en)
|
2018-03-30 |
2019-10-03 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
ES2964399T3
(es)
*
|
2018-05-16 |
2024-04-05 |
Provectus Pharmatech Inc |
Actividad antitumoral in vitro y xenoinjerto de un xanteno halogenado contra tumores sólidos pediátricos refractarios
|
|
WO2019229745A1
(en)
|
2018-05-27 |
2019-12-05 |
Biolinerx Ltd. |
Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
BR112021005769A2
(pt)
|
2018-09-25 |
2021-07-06 |
Harpoon Therapeutics Inc |
proteínas de ligação a dll3 e métodos de uso
|
|
KR20210081384A
(ko)
|
2018-10-23 |
2021-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
US20220001026A1
(en)
|
2018-11-08 |
2022-01-06 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
AU2019379325B2
(en)
|
2018-11-16 |
2025-04-24 |
Genexine, Inc. |
Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
|
|
KR20210092769A
(ko)
|
2018-11-16 |
2021-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항-nkg2a 항체 및 그의 용도
|
|
WO2020109328A1
(en)
|
2018-11-26 |
2020-06-04 |
Debiopharm International S.A. |
Combination treatment of hiv infections
|
|
GB201819853D0
(en)
*
|
2018-12-05 |
2019-01-23 |
Innovation Ulster Ltd |
Therapy
|
|
JP7625521B2
(ja)
|
2018-12-28 |
2025-02-03 |
トランスジーン |
ｍ２欠陥ポックスウイルス
|
|
WO2020198672A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
KR20220016156A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
US20220348653A1
(en)
|
2019-09-22 |
2022-11-03 |
Bristol-Myers Squibb Company |
Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
BR112022008191A2
(pt)
|
2019-11-08 |
2022-07-12 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para melanoma
|
|
MX2022005828A
(es)
*
|
2019-11-19 |
2022-07-04 |
Provectus Pharmatech Inc |
Composicion y metodo para tratamiento de canceres hematologicos.
|
|
US11419844B2
(en)
|
2019-11-19 |
2022-08-23 |
Provectus Pharmatech, Inc. |
Halogenated xanthene composition and method for treating hematologic cancers
|
|
US12064507B2
(en)
|
2019-11-19 |
2024-08-20 |
Provectus Pharmatech, Inc. |
Composition and method for oral treatment of leukemia
|
|
EP4076529A1
(en)
|
2019-12-19 |
2022-10-26 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｌ－１０およびその使用
|
|
CA3172124A1
(en)
*
|
2020-03-26 |
2021-09-30 |
Aru NARENDRAN |
Uses of halogenated xanthenes in oncology and virology
|
|
US11938182B2
(en)
|
2020-03-26 |
2024-03-26 |
Provectus Pharmatech, Inc. |
Halogenated xanthenes as vaccine adjuvants
|
|
WO2021243207A1
(en)
|
2020-05-28 |
2021-12-02 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
|
AU2021331476A1
(en)
|
2020-08-28 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
KR20230061430A
(ko)
|
2020-08-31 |
2023-05-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 면역요법
|
|
IL301907A
(en)
|
2020-10-23 |
2023-06-01 |
Bristol Myers Squibb Co |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
SI4267105T1
(sl)
|
2020-12-28 |
2025-07-31 |
Bristol-Myers Squibb Company |
Sestave protiteles in načini njihove uporabe
|
|
CA3196999A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Methods of treating tumors
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
CN118176214A
(zh)
|
2021-10-29 |
2024-06-11 |
百时美施贵宝公司 |
血液癌症的lag-3拮抗剂疗法
|
|
KR20240135661A
(ko)
|
2022-01-26 |
2024-09-11 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 조합 요법
|
|
WO2023161453A1
(en)
|
2022-02-24 |
2023-08-31 |
Amazentis Sa |
Uses of urolithins
|
|
CA3251366A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol Myers Squibb Co |
POLYTHERAPY AGAINST COLORECTAL CARCINOMA
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
CA3258064A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol Myers Squibb Co |
ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
|
|
KR20250034101A
(ko)
|
2022-07-01 |
2025-03-10 |
트랜스진 |
계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
CN120731228A
(zh)
|
2022-12-21 |
2025-09-30 |
百时美施贵宝公司 |
肺癌的组合疗法
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025184211A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025202222A1
(en)
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|